Safety and Effectiveness of Long-term Allopurinol – Thiopurine Maintenance Treatment in In fl ammatory Bowel Disease
暂无分享,去创建一个
D. Rubin | G. Bouma | F. Hoentjen | A. A. Bodegraven | M. Seinen | S. Hanauer | N. D. Boer | Laura E. Harrell
[1] D. Rubin,et al. Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction , 2011, Digestive Diseases and Sciences.
[2] G. Peters,et al. Allopurinol Enhances the Activity of Hypoxanthine-Guanine Phosphoribosyltransferase in Inflammatory Bowel Disease Patients During Low-Dose Thiopurine Therapy: Preliminary Data of an Ongoing Series , 2011, Nucleosides, nucleotides & nucleic acids.
[3] J. Sanderson,et al. A Biochemical Mechanism for the Role of Allopurinol in TPMT Inhibition , 2011 .
[4] S. Vikingsson,et al. The Role of Inosine-5′-Monophosphate Dehydrogenase in Thiopurine Metabolism in Patients With Inflammatory Bowel Disease , 2011, Therapeutic drug monitoring.
[5] J. V. van Ginkel,et al. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts , 2010, Inflammatory bowel diseases.
[6] M. Schwab,et al. Influence of 5‐aminosalicylic acid on 6‐thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy , 2010, British journal of pharmacology.
[7] N. D. de Boer,et al. Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] J. Sanderson,et al. Low‐dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.
[9] G. Peters,et al. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. , 2009, Current drug metabolism.
[10] M. Schwartz,et al. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[11] A. Eriksson,et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease , 2009, Alimentary pharmacology & therapeutics.
[12] J. Sanderson,et al. Long‐term outcome of using allopurinol co‐therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.
[13] J. Gisbert,et al. Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review , 2008, The American Journal of Gastroenterology.
[14] C. Lees,et al. Tolerability and safety of mercaptopurine in azathioprine‐intolerant patients with inflammatory bowel disease , 2007, Alimentary pharmacology & therapeutics.
[15] C. Mulder,et al. Dose-Dependent Influence of 5-Aminosalicylates on Thiopurine Metabolism , 2007, The American Journal of Gastroenterology.
[16] S. Hanauer,et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] J. Lewis,et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.
[18] P. Söderkvist,et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease , 2006, Gut.
[19] J. Duley,et al. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine , 2005, Alimentary pharmacology & therapeutics.
[20] S. Hanauer,et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.
[21] Michel Eichelbaum,et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. , 2004, Pharmacogenetics.
[22] D. McGovern,et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. , 2002, Gastroenterology.
[23] T. Bayless,et al. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease , 2001, Gut.
[24] S. Targan,et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.
[25] R. D. De Abreu,et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[26] R. Boulieu,et al. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. , 1998, Clinical chemistry.
[27] L. Lennard,et al. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. , 1992, Journal of chromatography.